顺铂、培美曲塞治疗60例非小细胞肺癌末期患者临床分析

Clinical analysis of cisplatin, pemetrexed in treatment of 60 cases of patients with advanced non-small cell lung cancer

目的：评价非小细胞肺癌末期患者施以培美曲塞以及顺铂联合方案治疗的临床意义。方法2013年10月至2016年1月因患有非小细胞肺癌进入我院接受治疗的末期患者共60例，随机分为两组：观察组31例，施以培美曲塞与顺铂联合方案治疗，常规组29例，施以顺铂与吉西他滨联合方案治疗，分析两组联合用药方案治疗质量与预后情况。结果联合治疗结束后，观察组中入选对象疾病缓解率为51．61％（16／31），常规组入选对象疾病缓解率44．83％（13／29），两组疾病缓解率差异无统计学意义（ z＝0．276，P＞0．05）。此外，观察组中胃肠道不良反应、中性粒细胞计数异常降低、血小板计数异常降低、脱发、感染、贫血、皮疹以及乏力发生率分别为9．68％（3／31）、6．45％（2／31）、3．23％（1／31）、6．45％（2／31）、3．23％（1／31）、16．13％（5／31）、3．23％（1／31）、16．13％（5／31），常规组分别为34．48％（10／29）、34．48％（10／29）、20．69％（6／29）、24．14％（7／29）、20．69％（6／29）、48．28％（14／29）、20．69％（6／29）、48．28％（14／29），培美曲塞与顺铂联合用药方案临床价值更为突出（χ2值分别为5．432、7．358、4．434、3．676、4．434、7．156、4．434、7．156，P均＜0．05）。结论将培美曲塞与顺铂联合给药方案应用于非小细胞肺癌末期患者中，除能提升其疾病缓解率以外，还有助于改善非小细胞肺癌末期患者临床指征与生存质量，避免不良症状发生，因此在非小细胞肺癌末期患者中有持续应用的价值。

Objective To evaluate the clinical significance of pemetrexed and cisplatin combination therapy on patients with advanced non?small cell lung cancer. Methods Sixty cases patients with non?small cell lung cancer who were treated in Liaoning Cancer Hospital and Institute from October 2013 to January 2016 were selected and randomly divided into two groups:analysis group( n=31 cases,pemetrexed and cisplatin combina?tion therapy) and normal group(n=29 cases,cisplatin and gemcitabine combination therapy). The treatment quality and prognosis of combination therapy of two groups were analyzed. Results After the combination treat?ment,selected objects disease remission rate of the analysis group was 51. 61%( 16/31) ,of the control group was 44. 83%(13/29),the difference was significant(z=0. 276,P>0. 0. 05). In addition,gastrointestinal adverse re?actions,abnormal lower neutrophil count,platelet count abnormal lower,hair loss,infection,anemia,skin rashes,&nbsp;fatigue and other adverse symptoms probability of the analysis group were 9. 68%( 3/31 ) , 6. 45%( 2/31 ) , 3. 23%(1/31),6. 45%(2/31),3. 23%(1/31),16. 13%(5/31),3. 23% (1/31) and 16. 13% (5/31),re?spectively,of the normal group were 34. 48%(10/29),34. 48%(10/29),20. 69%(6/29),24. 14%(7/29), 20. 69%(6/29),48. 28%(14/29),20. 69%(6/29) and 48. 28% (14/29),respectively,the clinical value of pemetrexed and cisplatin combination regimen was more outstanding(χ2=5. 432,7. 358,4. 434,3. 676,4. 434, 7. 156,4. 434,7. 156; P<0. 05) . Conclusion The pemetrexed and cisplatin combination regimen applied to non?small cell lung cancer patients stage,in addition to enhance its remission rate,it also helps to improve the non?small cell lung cancer stage patients’ clinical indications and quality of life,avoid adverse symptoms occur, so it is worth continuing the application in non?small cell lung cancer stage patients.